Drugs / [99mTc]Tc-HYNIC-FAPI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07457541 | Feb → Dec 2026 expected | breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm | Tomsk National Research Medical Center of the Russian Academy of Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [99mTc]Tc-HYNIC-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07457541 ↗ |
| Modality | Diagnostic / imaging agent | “SPECT/CT Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI” NCT07457541 ↗ |
| Route | Intravenous | “One single intravenous injection of \[99mTc\]Tc-HYNIC-FAPI, followed by gamma camera imaging after 2, 4, 6 and 24 hours.” NCT07457541 ↗ |